NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Site-Specific Glycan-Conjugated NISTmAb Antibody Drug Conjugate Standards
Published
Author(s)
Brian Agnew, Shanhua Lin, Robert Aggeler, John E. Schiel, Catherine Mouchahoir
Abstract
Antibody drug conjugates (ADCs) represent a rapidly growing modality for the treatment of numerous oncology indications. The complexity of analytical characterization method development is increased due to the potential for synthetic intermediates and process related impurities. In addition, the cytotoxicity of such materials provides an additional challenge with regard to handling products and/or sharing materials with analytical collaborators and/or vendors for technology development. Herein we have utilized a site-specific chemoenzymatic glycoconjugation strategy for preparing ADC mimetics comprised of the NIST monoclonal antibody (NIStmAb) conjugated to non-cytotoxic payloads representing both small molecules and peptides. The materials were exhaustively characterized with high resolution mass spectrometry based approaches to demonstrate the utility each analytical method for confirming the conjugation fidelity as well as deep characterization of synthetic intermediates and impurities arising from intentional payload raw material heterogeneity. These materials therefore represent a widely available test metric to develop novel ADC analytical methods as well a platform to discuss best practices for extensive characterization.
Agnew, B.
, Lin, S.
, Aggeler, R.
, Schiel, J.
and Mouchahoir, C.
(2021),
Site-Specific Glycan-Conjugated NISTmAb Antibody Drug Conjugate Standards, Analytical Chemistry, [online], https://doi.org/10.1007/s00216-021-03460-y, https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=931190
(Accessed October 14, 2025)